Meta-analysis of 10 RCTs (7,847 patients) with advanced ovarian cancer: anti-PD-1/PD-L1 agents did not significantly improve progression-free survival vs control (HR 0.98, 95% CI 0.85-1.12), first-line or recurrent, nor in PD-L1-positive, BRCA or HRD groups.
Meta-analysisn = 7,847
Vida et al. Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials